Jennifer Tobin

628 total citations
14 papers, 263 citations indexed

About

Jennifer Tobin is a scholar working on Hematology, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Jennifer Tobin has authored 14 papers receiving a total of 263 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 6 papers in Molecular Biology and 3 papers in Infectious Diseases. Recurrent topics in Jennifer Tobin's work include Acute Myeloid Leukemia Research (5 papers), Histone Deacetylase Inhibitors Research (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Jennifer Tobin is often cited by papers focused on Acute Myeloid Leukemia Research (5 papers), Histone Deacetylase Inhibitors Research (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Jennifer Tobin collaborates with scholars based in United States and Germany. Jennifer Tobin's co-authors include Henrik C. Hansen, Sarah Attwell, Ravi Jahagirdar, Norman C.W. Wong, Raymond Yu, Kevin G. McLure, Gregory S. Wagner, Peter R. Young, Jonathan A. Gutman and Salman Azhar and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Jennifer Tobin

14 papers receiving 253 citations

Peers

Countries citing papers authored by Jennifer Tobin

Since Specialization

Citations

This map shows the geographic impact of Jennifer Tobin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Tobin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Tobin more than expected).

Fields of papers citing papers by Jennifer Tobin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Tobin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Tobin. The network helps show where Jennifer Tobin may publish in the future.

Co-authorship network of co-authors of Jennifer Tobin

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Tobin. A scholar is included among the top collaborators of Jennifer Tobin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Tobin. Jennifer Tobin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Results from a Phase (Ph) 1 Clinical Study of the All-Oral Regimen of CC-486 and Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia 2023 ·Blood ·Maria L. Amaya, Christine M. McMahon, Marc Schwartz, Jonathan A. Gutman, (unknown), Jennifer Tobin, Austin E. Gillen, Anagha Inguva Sheth, Brett M. Stevens, Clayton A. Smith, Craig T. Jordan, Daniel A. Pollyea	2
2	Results from a phase (Ph) 1 clinical study of the all-oral regimen of CC-486 and venetoclax for acute myeloid leukemia (AML). 2023 ·Journal of Clinical Oncology ·Maria L. Amaya, Christine M. McMahon, Jonathan A. Gutman, Brett M. Stevens, (unknown), Jennifer Tobin, Clayton A. Smith, Craig T. Jordan, Daniel A. Pollyea	1
3	Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse 2023 ·Bone Marrow Transplantation ·Andrew Kent, Marc Schwartz, Christine M. McMahon, Maria L. Amaya, Clayton A. Smith, Jennifer Tobin, (unknown), (unknown), (unknown), Daniel A. Pollyea, Jonathan A. Gutman	16
4	Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia 2021 ·Cancer Reports ·(unknown), Diana Abbott, (unknown), Jennifer Tobin, Angela Falco, (unknown), Manali Kamdar	4
5	Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists 2020 ·Journal of Oncology Pharmacy Practice ·Valerie Relias, Ali McBride, (unknown), Shilpa Paul, (unknown), (unknown), Jennifer Tobin, (unknown), (unknown), Ilene Galinsky	2
6	Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population 2019 ·Biology of Blood and Marrow Transplantation ·Taylor Morrisette, (unknown), Matthew A. Miller, Scott W. Mueller, Valida Bajrovic, Maheen Z. Abidi, Esther Benamu, (unknown), Gerard R. Barber, (unknown), Jennifer Tobin, Douglas N. Fish, Jonathan A. Gutman	30
7	Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation 2019 ·Bone Marrow Transplantation ·(unknown), (unknown), Jennifer MacDonald, Maheen Z. Abidi, Esther Benamu, Valida Bajrovic, Enkhtsetseg Purev, (unknown), Jennifer Tobin, (unknown), (unknown), Matthew W. Miller, Adriana Weinberg, Jonathan A. Gutman	30
8	Successful treatment of disseminated Rosai-Dorfman disease with siltuximab 2018 ·Haematologica ·Hannah Lee, (unknown), Kavita Garg, Zenggang Pan, Jennifer Tobin, William A. Robinson	2
9	Post Transplant Prophylaxis with High Dose Valacyclovir through Day 100 Versus Day of Post Transplant Hospital Discharge Decreases Cytomegalovirus Reactivation in Adult Umbilical Cord Blood Transplant Recipients 2018 ·Blood ·(unknown), Jennifer MacDonald, (unknown), Jennifer Tobin, Matthew W. Miller, Maheen Z. Abidi, Esther Benamu, Enkhtsetseg Purev, (unknown), Jonathan A. Gutman	1
10	RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease 2017 ·Molecular Pharmacology ·Ravi Jahagirdar, Sarah Attwell, Suzana Marušić, Alison M. Bendele, Narmada Shenoy, Kevin G. McLure, Dean Gilham, Karen Norek, Henrik C. Hansen, Raymond Yu, Jennifer Tobin, Gregory S. Wagner, Peter R. Young, Norman C.W. Wong, Ewelina Kulikowski	48
11	Abstract LB-038: Preclinical development and clinical validation of a whole blood pharmacodynamic marker assay for the BET bromodomain inhibitor ZEN-3694 in metastatic castration-resistant prostate cancer (mCRPC) patients 2017 ·Cancer Research ·Laura Tsujikawa, Karen Norek, Cyrus Calosing, Sarah Attwell, Dean Gilham, Nimisha Sharma, Jennifer Tobin, (unknown), Ravi Jahagirdar, Sanjay Lakhotia, Henrik C. Hansen, Eric Campeau	8
12	Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series 2015 ·Leukemia & lymphoma ·Brett M. Stevens, Julia E. Maxson, Jeffrey Tyner, Clayton A. Smith, Jonathan A. Gutman, William A. Robinson, Craig T. Jordan, (unknown), Karen Swisshelm, Jennifer Tobin, Qi Wei, Jeffrey Schowinsky, (unknown), (unknown), Daniel A. Pollyea	8
13	A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice 2014 ·Atherosclerosis ·Ravi Jahagirdar, Haiyan Zhang, Salman Azhar, Jennifer Tobin, Sarah Attwell, Raymond Yu, (unknown), Kevin G. McLure, Henrik C. Hansen, Gregory S. Wagner, Peter R. Young, (unknown), Norman C.W. Wong, Jan Johansson	96
14	Herodes Attikos and the City of Athens 1997 ·Jennifer Tobin	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact